nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—MAP2K2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00194	0.00194	CbGpPWpGaD
Bosutinib—MAP2K2—DAP12 signaling—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Bosutinib—FYN—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Bosutinib—MAP3K7—B Cell Activation—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Bosutinib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00191	0.00191	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.0019	0.0019	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Bosutinib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00187	0.00187	CbGpPWpGaD
Bosutinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Bosutinib—FYN—Downstream signal transduction—FRS2—nasal cavity cancer	0.00184	0.00184	CbGpPWpGaD
Bosutinib—FYN—Signaling by FGFR—FRS2—nasal cavity cancer	0.00183	0.00183	CbGpPWpGaD
Bosutinib—MAP2K1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00183	0.00183	CbGpPWpGaD
Bosutinib—FYN—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00182	0.00182	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00182	0.00182	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—MAP2K2—DAP12 interactions—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—FYN—DAP12 signaling—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Bosutinib—MAP2K1—DAP12 signaling—FRS2—nasal cavity cancer	0.0018	0.0018	CbGpPWpGaD
Bosutinib—ERBB3—Signaling by NGF—FRS2—nasal cavity cancer	0.0018	0.0018	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by EGFR—FRS2—nasal cavity cancer	0.0018	0.0018	CbGpPWpGaD
Bosutinib—FYN—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Bosutinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Bosutinib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Bosutinib—EGFR—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Bosutinib—SRMS—Immune System—FRS2—nasal cavity cancer	0.00176	0.00176	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Bosutinib—LYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00173	0.00173	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00173	0.00173	CbGpPWpGaD
Bosutinib—FYN—DAP12 interactions—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Bosutinib—FYN—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Bosutinib—FYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Bosutinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Bosutinib—SYK—Innate Immune System—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Bosutinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Bosutinib—MAP2K1—DAP12 interactions—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Bosutinib—EGFR—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Bosutinib—FYN—Signaling by EGFR—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—CXCL11—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Bosutinib—FYN—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Bosutinib—PRKCQ—Innate Immune System—FRS2—nasal cavity cancer	0.00167	0.00167	CbGpPWpGaD
Bosutinib—FYN—Signaling by PDGF—FRS2—nasal cavity cancer	0.00167	0.00167	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00167	0.00167	CbGpPWpGaD
Bosutinib—EGFR—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Bosutinib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00164	0.00164	CbGpPWpGaD
Bosutinib—SYK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00163	0.00163	CbGpPWpGaD
Bosutinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00163	0.00163	CbGpPWpGaD
Bosutinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00161	0.00161	CbGpPWpGaD
Bosutinib—PRKCQ—Adaptive Immune System—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Bosutinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Bosutinib—LYN—B Cell Activation—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—CXCL11—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Bosutinib—EGFR—Downstream signal transduction—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
Bosutinib—EGFR—Signaling by FGFR—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Bosutinib—FYN—B Cell Activation—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Bosutinib—EGFR—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Bosutinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Bosutinib—EGFR—DAP12 signaling—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Bosutinib—CSK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00155	0.00155	CbGpPWpGaD
Bosutinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Bosutinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00153	0.00153	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00153	0.00153	CbGpPWpGaD
Bosutinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Bosutinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Bosutinib—PHKG1—Disease—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Bosutinib—FYN—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Bosutinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Bosutinib—SRC—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Bosutinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0015	0.0015	CbGpPWpGaD
Bosutinib—IRAK1—Signaling by NGF—FRS2—nasal cavity cancer	0.0015	0.0015	CbGpPWpGaD
Bosutinib—TXK—Immune System—FRS2—nasal cavity cancer	0.0015	0.0015	CbGpPWpGaD
Bosutinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Bosutinib—SRC—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Bosutinib—EGFR—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Bosutinib—EGFR—DAP12 interactions—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Bosutinib—EGFR—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Bosutinib—EGFR—Signaling by EGFR—FRS2—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Bosutinib—EGFR—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00145	0.00145	CbGpPWpGaD
Bosutinib—TBK1—Innate Immune System—FRS2—nasal cavity cancer	0.00145	0.00145	CbGpPWpGaD
Bosutinib—EGFR—Signaling by PDGF—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Bosutinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00142	0.00142	CbGpPWpGaD
Bosutinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00142	0.00142	CbGpPWpGaD
Bosutinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00142	0.00142	CbGpPWpGaD
Bosutinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00141	0.00141	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—FRS2—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Bosutinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Bosutinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Bosutinib—EGFR—B Cell Activation—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Bosutinib—SRC—Downstream signal transduction—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Bosutinib—BTK—Innate Immune System—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Bosutinib—SRC—Signaling by FGFR—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Bosutinib—SRC—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00132	0.00132	CbGpPWpGaD
Bosutinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Bosutinib—EGFR—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Bosutinib—BTK—Adaptive Immune System—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Bosutinib—IRAK4—Innate Immune System—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—CXCL11—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Bosutinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Bosutinib—SRC—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Bosutinib—SRC—Signaling by EGFR—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Bosutinib—HCK—Innate Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by NGF—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Bosutinib—SRC—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Bosutinib—BCR—Disease—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Bosutinib—SRC—Signaling by PDGF—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Bosutinib—ERBB4—Innate Immune System—FRS2—nasal cavity cancer	0.00117	0.00117	CbGpPWpGaD
Bosutinib—FYN—Signaling by NGF—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by NGF—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Bosutinib—IKBKE—Immune System—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Bosutinib—ERBB4—Adaptive Immune System—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Bosutinib—FGR—Innate Immune System—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Bosutinib—SRC—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Bosutinib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00108	0.00108	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—CXCL11—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Bosutinib—EGFR—Signaling by NGF—FRS2—nasal cavity cancer	0.001	0.001	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—FRS2—nasal cavity cancer	0.000994	0.000994	CbGpPWpGaD
Bosutinib—SYK—Immune System—FRS2—nasal cavity cancer	0.000991	0.000991	CbGpPWpGaD
Bosutinib—ERBB3—Adaptive Immune System—FRS2—nasal cavity cancer	0.000987	0.000987	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—FRS2—nasal cavity cancer	0.000973	0.000973	CbGpPWpGaD
Bosutinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.000967	0.000967	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—FRS2—nasal cavity cancer	0.000943	0.000943	CbGpPWpGaD
Bosutinib—CSK—Immune System—FRS2—nasal cavity cancer	0.00094	0.00094	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—FRS2—nasal cavity cancer	0.000915	0.000915	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—FRS2—nasal cavity cancer	0.000903	0.000903	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—FRS2—nasal cavity cancer	0.000899	0.000899	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—FRS2—nasal cavity cancer	0.000898	0.000898	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—FRS2—nasal cavity cancer	0.000898	0.000898	CbGpPWpGaD
Bosutinib—CSK—Disease—FRS2—nasal cavity cancer	0.000868	0.000868	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—FRS2—nasal cavity cancer	0.000867	0.000867	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—FRS2—nasal cavity cancer	0.000862	0.000862	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—CXCL11—nasal cavity cancer	0.000862	0.000862	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—FRS2—nasal cavity cancer	0.000856	0.000856	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—FRS2—nasal cavity cancer	0.000856	0.000856	CbGpPWpGaD
Bosutinib—TBK1—Immune System—FRS2—nasal cavity cancer	0.000843	0.000843	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—FRS2—nasal cavity cancer	0.000827	0.000827	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—FRS2—nasal cavity cancer	0.000808	0.000808	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—FRS2—nasal cavity cancer	0.000806	0.000806	CbGpPWpGaD
Bosutinib—BTK—Immune System—FRS2—nasal cavity cancer	0.000786	0.000786	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—FRS2—nasal cavity cancer	0.000774	0.000774	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000762	0.000762	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—FRS2—nasal cavity cancer	0.000754	0.000754	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—FRS2—nasal cavity cancer	0.000751	0.000751	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CXCL11—nasal cavity cancer	0.000745	0.000745	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.000734	0.000734	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—FRS2—nasal cavity cancer	0.000726	0.000726	CbGpPWpGaD
Bosutinib—HCK—Immune System—FRS2—nasal cavity cancer	0.000721	0.000721	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000713	0.000713	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000707	0.000707	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—FRS2—nasal cavity cancer	0.000704	0.000704	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.000687	0.000687	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000682	0.000682	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.000682	0.000682	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—FRS2—nasal cavity cancer	0.000679	0.000679	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—FRS2—nasal cavity cancer	0.000673	0.000673	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00067	0.00067	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—FRS2—nasal cavity cancer	0.00067	0.00067	CbGpPWpGaD
Bosutinib—HCK—Disease—FRS2—nasal cavity cancer	0.000666	0.000666	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—FRS2—nasal cavity cancer	0.000663	0.000663	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00066	0.00066	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—FRS2—nasal cavity cancer	0.000659	0.000659	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CXCL11—nasal cavity cancer	0.000657	0.000657	CbGpPWpGaD
Bosutinib—BLK—Immune System—FRS2—nasal cavity cancer	0.000653	0.000653	CbGpPWpGaD
Bosutinib—FGR—Immune System—FRS2—nasal cavity cancer	0.000651	0.000651	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.000646	0.000646	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—FRS2—nasal cavity cancer	0.000641	0.000641	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.000636	0.000636	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—FRS2—nasal cavity cancer	0.000629	0.000629	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—FRS2—nasal cavity cancer	0.000629	0.000629	CbGpPWpGaD
Bosutinib—ERBB4—Disease—FRS2—nasal cavity cancer	0.000627	0.000627	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000619	0.000619	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—FRS2—nasal cavity cancer	0.000607	0.000607	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—FRS2—nasal cavity cancer	0.000599	0.000599	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000585	0.000585	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000577	0.000577	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—FRS2—nasal cavity cancer	0.000572	0.000572	CbGpPWpGaD
Bosutinib—ERBB3—Disease—FRS2—nasal cavity cancer	0.000553	0.000553	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.000552	0.000552	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—FRS2—nasal cavity cancer	0.00055	0.00055	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000547	0.000547	CbGpPWpGaD
Bosutinib—PTK2—Immune System—FRS2—nasal cavity cancer	0.000533	0.000533	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00053	0.00053	CbGpPWpGaD
Bosutinib—YES1—Immune System—FRS2—nasal cavity cancer	0.000526	0.000526	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CXCL11—nasal cavity cancer	0.000515	0.000515	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—FRS2—nasal cavity cancer	0.000508	0.000508	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—FRS2—nasal cavity cancer	0.000499	0.000499	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—FRS2—nasal cavity cancer	0.000488	0.000488	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—FRS2—nasal cavity cancer	0.000469	0.000469	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—FRS2—nasal cavity cancer	0.000469	0.000469	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00045	0.00045	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—FRS2—nasal cavity cancer	0.000439	0.000439	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.000439	0.000439	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—FRS2—nasal cavity cancer	0.000433	0.000433	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.00043	0.00043	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.000423	0.000423	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000421	0.000421	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000417	0.000417	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—FRS2—nasal cavity cancer	0.00041	0.00041	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FRS2—nasal cavity cancer	0.000402	0.000402	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.000402	0.000402	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.0004	0.0004	CbGpPWpGaD
Bosutinib—LYN—Immune System—FRS2—nasal cavity cancer	0.000392	0.000392	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.00039	0.00039	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FRS2—nasal cavity cancer	0.000387	0.000387	CbGpPWpGaD
Bosutinib—FYN—Immune System—FRS2—nasal cavity cancer	0.000386	0.000386	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FRS2—nasal cavity cancer	0.000384	0.000384	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FRS2—nasal cavity cancer	0.000379	0.000379	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.00037	0.00037	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL11—nasal cavity cancer	0.000366	0.000366	CbGpPWpGaD
Bosutinib—FYN—Disease—FRS2—nasal cavity cancer	0.000356	0.000356	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FRS2—nasal cavity cancer	0.000354	0.000354	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.000352	0.000352	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000345	0.000345	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FRS2—nasal cavity cancer	0.00034	0.00034	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FRS2—nasal cavity cancer	0.000333	0.000333	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000322	0.000322	CbGpPWpGaD
Bosutinib—LCK—Immune System—FRS2—nasal cavity cancer	0.000321	0.000321	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL11—nasal cavity cancer	0.000312	0.000312	CbGpPWpGaD
Bosutinib—EGFR—Disease—FRS2—nasal cavity cancer	0.000308	0.000308	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FRS2—nasal cavity cancer	0.000304	0.000304	CbGpPWpGaD
Bosutinib—LCK—Disease—FRS2—nasal cavity cancer	0.000297	0.000297	CbGpPWpGaD
Bosutinib—SRC—Immune System—FRS2—nasal cavity cancer	0.000284	0.000284	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FRS2—nasal cavity cancer	0.000265	0.000265	CbGpPWpGaD
Bosutinib—SRC—Disease—FRS2—nasal cavity cancer	0.000263	0.000263	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000259	0.000259	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000253	0.000253	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FRS2—nasal cavity cancer	0.00025	0.00025	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FRS2—nasal cavity cancer	0.000248	0.000248	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FRS2—nasal cavity cancer	0.000216	0.000216	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000208	0.000208	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FRS2—nasal cavity cancer	0.000184	0.000184	CbGpPWpGaD
